Alaunos Therapeutics, Inc. Debt Conversion, Converted Instrument, Amount
Alaunos Therapeutics, Inc. (TCRT) reported Debt Conversion, Converted Instrument, Amount of $54.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2017-02-16
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2012-12-31 was $0.00.
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2012-06-30 was $370.00K, a 560.71% increase year-over-year.
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2012-03-31 was $42.00K, a 79.90% decline year-over-year.
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2014 was $54.00K.
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2012 was $412.00K, a 35.97% increase from fiscal 2011.
- Alaunos Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2011 was $303.00K, a 518.37% increase from fiscal 2010.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month | Debt Conversion, Converted Instrument, Amount 85 month | Debt Conversion, Converted Instrument, Amount 94 month | Debt Conversion, Converted Instrument, Amount 97 month | Debt Conversion, Converted Instrument, Amount 100 month | Debt Conversion, Converted Instrument, Amount 103 month | Debt Conversion, Converted Instrument, Amount 106 month | Debt Conversion, Converted Instrument, Amount 109 month | Debt Conversion, Converted Instrument, Amount 112 month | Debt Conversion, Converted Instrument, Amount 115 month | Debt Conversion, Converted Instrument, Amount 118 month | Debt Conversion, Converted Instrument, Amount 121 month | Debt Conversion, Converted Instrument, Amount 124 month | Debt Conversion, Converted Instrument, Amount 127 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | $54.00K 10-K · filed 2017-02-16 | ||||||||||||||||
| 2014-03-31 | $764.00K 10-Q · filed 2014-05-08 | ||||||||||||||||
| 2013-12-31 | $0.00 10-K · filed 2014-03-03 | $764.00K 10-K · filed 2014-03-03 | |||||||||||||||
| 2013-09-30 | $352.00K 10-Q · filed 2013-10-22 | ||||||||||||||||
| 2013-06-30 | $352.00K 10-Q · filed 2013-08-08 | ||||||||||||||||
| 2013-03-31 | $352.00K 10-Q · filed 2013-05-07 | ||||||||||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $0.00 derived: sum of 2 quarters · filed 2015-02-26 | $370.00K derived: sum of 3 quarters · filed 2015-02-26 | $412.00K 10-K · filed 2015-02-26 | $352.00K 10-K · filed 2013-03-18 | ||||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-22 | $370.00K derived: sum of 2 quarters · filed 2013-10-22 | $412.00K 10-Q · filed 2013-10-22 | $412.00K derived: sum of 4 quarters · filed 2014-03-03 | $764.00K 10-Q · filed 2012-11-08 | ||||||||||||
| 2012-06-30 | $370.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $412.00K 10-Q · filed 2013-08-08 | $412.00K derived: sum of 3 quarters · filed 2014-03-03 | $450.00K derived: sum of 4 quarters · filed 2014-03-03 | $764.00K 10-Q/A · filed 2012-08-28 | ||||||||||||
| 2012-03-31 | $42.00K 10-Q · filed 2013-05-07 | $42.00K derived: sum of 2 quarters · filed 2014-03-03 | $80.00K derived: sum of 3 quarters · filed 2014-03-03 | $136.00K derived: sum of 4 quarters · filed 2014-03-03 | $394.00K 10-Q · filed 2012-05-03 | ||||||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $38.00K derived: sum of 2 quarters · filed 2014-03-03 | $94.00K derived: sum of 3 quarters · filed 2014-03-03 | $303.00K 10-K · filed 2014-03-03 | $352.00K 10-K · filed 2012-02-29 | ||||||||||||
| 2011-09-30 | $38.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-08 | $94.00K derived: sum of 2 quarters · filed 2012-11-08 | $303.00K 10-Q · filed 2012-11-08 | $303.00K derived: sum of 4 quarters · filed 2013-03-18 | $352.00K 10-Q · filed 2011-11-03 | ||||||||||||
| 2011-06-30 | $56.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-08-28 | $265.00K 10-Q/A · filed 2012-08-28 | $265.00K derived: sum of 3 quarters · filed 2013-03-18 | $265.00K derived: sum of 4 quarters · filed 2013-03-18 | $314.00K 10-Q/A · filed 2011-08-09 | ||||||||||||
| 2011-03-31 | $209.00K 10-Q · filed 2012-05-03 | $209.00K derived: sum of 2 quarters · filed 2013-03-18 | $209.00K derived: sum of 3 quarters · filed 2013-03-18 | ||||||||||||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $0.00 derived: sum of 2 quarters · filed 2013-03-18 | $49.00K 10-K · filed 2013-03-18 | ||||||||||||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-03 | $49.00K 10-Q · filed 2011-11-03 | $49.00K 10-Q · filed 2011-08-01 | ||||||||||||||
| 2010-06-30 | $49.00K 10-Q/A · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |